LZLei Zhang

Lei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lei Zhang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Guannan Ma

    Zhejiang Key Laboratory of Digital Technology in Medical Diagnostics

    3 shared publications
  • Songchen Zhao

    Department of Medical Oncology, Shanghai East Hospital, School of Medicine, Tongji University

    3 shared publications
  • Aiguo Wu

    Chinese Academy of Sciences

    2 shared publications
  • Jie Lin

    Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Zhejiang Engineering Research Center for Biomedical Materials at Ningbo Cixi Institute of Biomedical Engineering, Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, China

    2 shared publications
  • Dapeng Li

    Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China

    1 shared publication
  • Han Yan

    Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd., Hangzhou, Zhejiang, China

    1 shared publication

Latest Publications

  • Open Access

    An integrated analysis of SLC7A11 as a pan-cancer immunotherapeutic biomarker with experimental validation of its regulation by miR-148b-3p in breast cancer

    by Songchen Zhao, Miao Zheng, Guannan Ma, Kaifeng Niu, Lei Zhang

    Background: Identifying reliable biomarkers for immunotherapy response remains challenging. Solute carrier family 7 member 11 (SLC7A11), a key regulator of redox homeostasis and ferroptosis, demonstrates significant tumor-promoting potential across cancers, yet its pan-cancer associations with immunotherapy-related features and interaction with microRNAs in triple-negative breast cancer pathogenesis remain elusive. Methods: We systematically analyzed SLC7A11 expression across cancer types using TCGA and GTEx data, and evaluated its associations with immunotherapy-related features. Survival analyses were assessed in general and immunotherapy-treated cohorts. A miRNA regulatory network targeting SLC7A11 was constructed in breast cancer and the SLC7A11-miR-148b-3p axis was tested via in vitro experiments in triple-negative breast cancer (TNBC) cell models (MDA-MB-231 and MDA-MB-468). Results: Pan-cancer analysis revealed upregulation of SLC7A11 transcriptional expression in over 88% tumor types, and associations with established immunotherapy-related features, including tumor mutational burden, microsatellite instability, PD-L1 expression, and immune infiltration. Higher SLC7A11 expression was associated with improved response to immunotherapy, but inferior prognosis in most tumors, including breast cancer. In TNBC cell models, in vitro experiments supported that miR-148b-3p negatively regulated SLC7A11, and higher SLC7A11 expression was associated with increased glutathione levels, reduced lipid peroxidation, and enhanced cell survival under ferroptosis-inducing conditions. Conclusions: Our pan-cancer analyses reveal a potential biological link between SLC7A11, ferroptosis, and tumor immunity, generating the hypothesis that SLC7A11 may serve as a biomarker for immune checkpoint inhibitor response. In TNBC models, we identify the miR-148b-3p/SLC7A11 axis as a potential regulator of ferroptosis resistance based on in vitro findings, warranting further in vivo validation.

  • Open Access

    Metagenomic Next-Generation Sequencing Reveals Porphyromonas gingivalis in Geriatric Severe Pneumonia Complicated by Empyema: Case Report

    by Na Guo, Guannan Ma, Huimin Liu, Jingxuan Qiu, Yan Yu, Yunlei Gao, Zhong Yi, Zhirong Wan, Lei Zhang, Xiaorui Wu

    Background: Severe pneumonia with empyema in elderly patients presents diagnostic and therapeutic challenges. Traditional culture methods often fail to identify the causative pathogen, leading to delays in targeted treatment. Metagenomic next-generation sequencing (mNGS) has emerged as a powerful tool for detecting rare and fastidious pathogens. Case Presentation: We report a 77-year-old male with a history of chronic smoking and alcohol consumption who presented with a two-month history of cough, sputum production, and progressive dyspnea. His condition rapidly deteriorated with high fever and respiratory failure. Initial antibiotic therapy was ineffective, and multiple cultures of blood, sputum, and pleural fluid were negative. However, mNGS of blood and pleural fluid identified Porphyromonas gingivalis, a well-known periodontal pathogen rarely associated with pulmonary infections. The patient’s treatment was adjusted to include targeted anaerobic coverage (imipenem plus vancomycin) alongside chest tube drainage, leading to significant clinical improvement. Conclusion: This case highlights the clinical utility of mNGS in diagnosing culture-negative pulmonary infections. Porphyromonas gingivalis should be considered a potential pathogen in patients with severe pneumonia and empyema, particularly in those with poor oral hygiene or periodontal disease.


  • Multi-omics analysis unveils dysregulation of the tumor immune microenvironment and development of a machine learning-based multi-gene classifier for predicting lateral lymph node metastasis in papillary thyroid carcinoma

    by Qingxiang Yu, Weijing Hao, Yanbin He, Xianhui Ruan, Lin Liu, Xinwei Yun, Dapeng Li, Jingzhu Zhao, Wenfeng Cao, Yu Yin, et al.

    Purpose Lateral lymph node metastasis (LNM) critically influences surgical decision-making in papillary thyroid carcinoma (PTC). However, the sensitivity of preoperative imageological examination in detecting LNM remains suboptimal, necessitating the development of more accurate diagnostic and predictive tools. This study aims to identify multi-omics biomarkers and construct a predictive model for LNM. Methods We performed a comprehensive multi-omics analysis of 50 PTCs presenting with (LNM group) or without lateral lymph node metastases (LNN group) using whole exome sequencing and whole transcriptome sequencing. Results Younger age, larger tumor size, and lymphovascular invasion were associated with increased risk of LNM, while invasive follicular subtype was associated with lower risk of LNM. Genomic landscape analysis identified 23 LNM group specific driver mutations and 15 protective variants in the LNN group. Transcriptome analysis identified 444 differentially expressed genes associated with LNM. Weighted gene co-expression network analysis revealed a module that correlated negatively with LNM, with key genes significantly enriched in Notch signaling pathway and Apelin signaling pathway. Notably, elevated neutrophils in tumor immune microenvironment was strongly associated with high LNM risk, suggesting neutrophils as potential early predictors of lateral lymph node metastasis in PTC. A machine learning-based multi-gene classifier was developed to predict LNM, achieving excellent performance with an area under the curve (AUC) of 0.98 in the training set and 0.892 in the test set. Conclusions This study provides novel insights into the molecular characteristics of PTC associated with lateral lymph node metastasis, highlighting tumor-infiltrating neutrophils as an independent LNM predictor. The multi-gene classifier developed in this study demonstrates promising clinical utility for improving the accuracy of LNM prediction and guiding personalized treatment strategies in PTC.


  • Recent advances of metal cluster-based SERS probes for biomedical applications

    by Li Sun, Songchen Zhao, Shishuai Zheng, Lei Zhang, Jie Lin, Aiguo Wu

    This review summarizes the latest progress in the field of SERS, including advanced substrate materials and their enhancement mechanisms, with an emphasis on metal cluster-based SERS probes and their biomedical applications.


  • Open Access

    Multidrug-resistant ST11-KL64 hypervirulent Klebsiella pneumoniae with multiple bla- genes isolated from children's blood

    by \R\Nrongmu Luo, Guannan Ma, Qian Yu, Zhengqin Tian, Qihang Man, Xiangrong Shu, Xuetong Liu, Yupeng Shi, Lei Zhang, Jingbo Wang

    Introduction: Hypervirulent carbapenem-resistant Klebsiella pneumoniae (hv-CRKP) poses an increasing public health risk due to its high treatment difficulty and associated mortality, especially in bone marrow transplant (BMT) patients. The emergence of strains with multiple resistance mechanisms further complicates the management of these infections.Methods: We isolated and characterized a novel ST11-KL64 hv-CRKP strain from a pediatric bone marrow transplantation patient. Antimicrobial susceptibility testing was performed to determine resistance patterns. Comprehensive genomic analysis was conducted to identify plasmid types, virulence factors, and antimicrobial resistance genes, as well as potential resistance mechanisms associated with mutations and plasmid-mediated variants.Results: The isolated hv-CRKP strain exhibited multidrug resistance to carbapenem, tigecycline, and polymyxin. Genomic analysis revealed that the IncHI1B/repB plasmid carried virulence factors (rmpA, ΔrmpA2, iucABCD, iutA), while IncFII/IncR and IncFII plasmids harbored resistance genes [blaCTX-M-65, blaTEM-1B, rmtB, blaSHV-12, blaKPC-2, qnrS1, blaLAP-2, sul2, dfrA14, tet(A), tet(R)]. The coexistence of blaCTX-M-65, blaTEM-1B, blaSHV-12, blaLAP-2,and blaKPC-2 in one hv-CRKP strain is exceptionally rare. Additionally, the Tet(A)-S251A variant in the conjugative plasmid pTET-4 may confer tigecycline resistance. Mutations in MgrB, PhoPQ, and PmrABCDK were identified as potential contributors to increased polymyxin resistance. Interestingly, plasmid-encoded restriction-modification systems and Retron regions were identified, which could potentially confer phage resistance.Discussion: The combination of virulence and antimicrobial resistance factors in the ST11-KL64 hv-CRKP strain represents a significant challenge for treating immunocompromised pediatric patients. Particularly concerning is the resistance to polymyxin and tigecycline, which are often last-resort treatments for multidrug-resistant infections. The findings highlight the urgent need for effective surveillance, infection control measures, and novel therapeutic strategies to manage such hypervirulent and multidrug-resistant pathogens.


  • Open Access

    Oncocytic cell carcinoma of the thyroid with TERT promoter mutation presenting as asphyxia in an elderly: a case report

    by Xiqian Wang, Yingao Liu, Lijie Chen, Jie Zhang, Ruoyu Jiang, Lei Zhang, Han Yan

    Introduction: The prevalence of thyroid nodules and malignancies in the elderly is a growing concern. Thyroid nodules in this population have unique characteristics, requiring careful treatment strategies that balance risks and benefits. Oncocytic carcinoma of the thyroid (OCA) is a rare, aggressive subtype with diagnostic challenges.Methods: This case features an 84-year-old patient who presented with a neck mass and symptoms of asphyxia. Clinical evaluation, imaging studies, and biopsy were conducted to assess the nature of the thyroid lesion. Molecular testing, including genetic analysis, was performed to identify specific mutations associated with OCA and guide treatment decisions.Results: The patient was diagnosed with oncocytic carcinoma of the thyroid. The molecular testing revealed specific genetic mutations indicative of OCA, confirming the diagnosis. The presence of these mutations guided the treatment plan, emphasizing the importance of molecular diagnostics in managing thyroid malignancies, especially in the elderly.Discussion: This case illustrates the complexities of diagnosing and treating thyroid malignancies in the elderly. Biopsy and molecular testing provided diagnostic accuracy and informed treatment. Individualized approaches are essential for better outcomes, especially in aggressive subtypes, balancing the risks and benefits of intervention.


  • Open Access

    Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma

    by Qing-Xiang Yu, Wen-Jun Zhao, He-Yue Wang, Lei Zhang, Lan Qin, Jian-Li Han

    NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display promising therapeutic efficacy in NTRK-positive solid tumors. Although some NTRK fusion partners have been identified in thyroid cancer, the spectrum of NTRK fusion is not fully characterized. In this study, a dual NTRK3 fusion was identified by targeted RNA-Seq in a 47-year-old female patient with papillary thyroid carcinoma. The patient harbors a novel in-frame fusion between NTRK3 exon 13 and AJUBA exon 2, co-existing with a known in-frame fusion between ETV6 exon 4 and NTRK3 exon 14. The dual NTRK3 fusion was validated by Sanger sequencing and fluorescence in situ hybridization (FISH) but lack TRK protein expression as defined by pan-TRK immunohistochemistry (IHC). We supposed the pan-TRK IHC result to be falsely negative. In conclusion, we present the first case of a novel NTRK3-AJUBA fusion co-existing with a known ETV6-NTRK3 fusion in thyroid cancer. These findings extend the spectrum of translocation partners in NTRK3 fusion, and the effect of dual NTRK3 fusion on TRK inhibitor therapy and prognosis needs long-term follow-up.